Effects of a single course of deferoxamine in neuroblastoma patients

A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed. Within 2 days of completion of treatment responses were observed in 7 of 9 patients and there was no drug toxicity. These responses were a decrease in bone marrow infiltration and, in one patie...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1990-08, Vol.50 (16), p.4929
Main Authors: Donfrancesco, A, Deb, G, Dominici, C, Pileggi, D, Castello, M A, Helson, L
Format: Article
Language:English
Subjects:
Adolescent
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brain Neoplasms - drug therapy
Child
Child, Preschool
Deferoxamine - adverse effects
Deferoxamine - therapeutic use
Drug Evaluation
Female
Humans
Infant
Male
Neuroblastoma - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A phase II trial of a single 5-day course of deferoxamine in 9 patients with neuroblastomas was completed. Within 2 days of completion of treatment responses were observed in 7 of 9 patients and there was no drug toxicity. These responses were a decrease in bone marrow infiltration and, in one patient, a measurable reduction in her tumor mass. We conclude that deferoxamine given as an 8-h i.v. infusion daily for 5 days at 150 mg/kg/day has antitumor activity.
ISSN:0008-5472